Pharmacists Weigh Promise and Challenges of Finerenone for Patients With HFpEF
Pharmacy Times
JULY 24, 2025
Pharmacists are positioned to personalize HFpEF care through monitoring, patient-centered strategies, and shared decision-making, enhancing treatment adherence and outcomes. Finerenone, a nonsteroidal MRA, shows promise in reducing HF events and atrial fibrillation, offering potential benefits over steroidal MRAs like spironolactone.
Let's personalize your content